Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-75 vs FENTANYL-50
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression. It also interacts with kappa and delta receptors to a lesser extent.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA-approved for opioid-tolerant patients only).
Management of breakthrough pain in cancer patients (opioid-tolerant) (approved for transmucosal formulations),Anesthesia induction and maintenance (IV use),Premedication for anesthetic procedures,Off-label: Severe acute pain in emergency settings (e.g., procedural sedation),Off-label: Chronic pain management (transdermal patch only for opioid-tolerant patients)
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
50 mcg intravenously every 5-10 minutes as needed for breakthrough pain or for induction of anesthesia; for transdermal, 12-100 mcg/hour applied every 72 hours.
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Terminal elimination half-life: 3-12 hours (mean 7 hours); context: prolonged with continuous infusion or in elderly, hepatic impairment, or obesity due to accumulation in adipose tissue.
Primarily metabolized via CYP3A4 in the liver and intestinal mucosa to norfentanyl and other minor metabolites; undergoes extensive first-pass metabolism.
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Reduce dose by 50% and monitor.
GFR 30-60 m L/min: reduce dose by 25-50%; GFR <30 m L/min: avoid or reduce dose by 50-75% and monitor closely.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50%. Class C: Avoid use.
Risk of respiratory depression that may result in death; ensure proper patient selection, dosing, and monitoring. Avoid use in opioid non-tolerant patients. Accidental exposure can be fatal. Concomitant use with CNS depressants increases risk. Risk of abuse, misuse, addiction, and diversion. Neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of life-threatening respiratory depression from CYP3A4 inhibitors or discontinuation of CYP3A4 inducers.
Fetal risk cannot be ruled out. In first trimester, no clear evidence of major malformations from opioid analgesics, but data limited. Second and third trimesters: chronic use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS) postpartum. Use during labor may cause respiratory depression in neonate. Risk of preterm birth and low birth weight with prolonged use.
First trimester: Limited data, but animal studies show no structural teratogenicity at clinically relevant doses. Second/third trimester: Chronic exposure may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Avoid prolonged use.
DURAGESIC-75 delivers fentanyl at 75 mcg/hour transdermally. Do not use in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-hairy skin on upper torso or upper arm. Avoid heat sources (heating pads, hot tubs) as heat increases absorption. Onset ~12-24 hours; peak effect ~24-72 hours. Remove old patch before applying new; rotate sites. Do not cut or damage the patch. Monitor for serotonin syndrome if used with serotonergic drugs. For breakthrough pain, use immediate-release opioids not additional fentanyl patches.
Fentanyl 50 mcg/hr patch provides continuous systemic opioid delivery. Onset of action 12-24 hours; steady state in 72 hours. Do not cut or use damaged patches. Avoid heat sources (fever, heating pads, saunas) as they increase absorption and risk of overdose. Monitor for respiratory depression, especially in opioid-naïve patients. C max may increase by 25-40% with fever. Apply to non-irritated, non-hairy skin on upper torso. Use in opioid-tolerant patients only.
No interactions on record
No interactions on record
DURAGESIC-75 and FENTANYL-50 are distinct pharmacological agents. DURAGESIC-75 belongs to the Opioid Analgesic class and is primarily used for Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA-approved for opioid-tolerant patients only).. FENTANYL-50 belongs to the Opioid Agonist class and is primarily used for Management of breakthrough pain in cancer patients (opioid-tolerant) (approved for transmucosal formulations)Anesthesia induction and maintenance (IV use)Premedication for anesthetic proceduresOff-label: Severe acute pain in emergency settings (e.g., procedural sedation)Off-label: Chronic pain management (transdermal patch only for opioid-tolerant patients). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DURAGESIC-75 carries a safety status of Category C, whereas FENTANYL-50 safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily metabolized via CYP3A4 in the liver to norfentanyl (inactive) and other metabolites; minor contributions from CYP3A5. Less than 10% excreted unchanged in urine.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Renal: 75% (primarily as metabolites, <10% unchanged); Fecal: 9%; Biliary: minor contribution.
90-95% bound to alpha-1-acid glycoprotein and albumin
80-85% bound, primarily to alpha-1-acid glycoprotein and albumin.
6-7 L/kg, indicating extensive tissue distribution
3-8 L/kg (mean 4 L/kg); high Vd indicates extensive distribution into tissues including skeletal muscle and fat.
Fentanyl transdermal: 50-65% of patch content absorbed into systemic circulation
IV: 100%; Transdermal: 92% (relative to IV, absolute bioavailability ~92%); Transmucosal (buccal, sublingual): 50-70%; Intranasal: 70-90%; Oral: low (<50% due to first-pass metabolism).
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75% or avoid use.
Children ≥2 years: 12.5-25 mcg/hr initial, titrate based on need; max dose 25 mcg/hr for opioid-naive.
Intravenous: 0.5-2 mcg/kg per dose every 5-10 minutes as needed; transdermal: not recommended for children under 2 years; for children >2 years, start at 12 mcg/hour based on prior opioid exposure.
Initial dose reduction of 25-50%; titrate cautiously; avoid in frail elderly.
Starting dose should be 50-75% lower than in younger adults; titrate slowly; transdermal patch starting dose no higher than 25 mcg/hour; monitor for respiratory depression and cognitive impairment.
Black Box Warning: Risk of respiratory depression, addiction, abuse, and misuse; life-threatening respiratory depression and death can occur at any dose, especially with initial use or dose escalation. Concomitant use with CNS depressants (e.g., benzodiazepines, alcohol) may cause profound sedation, respiratory depression, coma, and death. Accidental exposure (especially in children) can be fatal.
No significant food interactions. Grapefruit juice may increase fentanyl levels via CYP3A4 inhibition; caution with high intake. Avoid alcohol due to additive CNS depression.
Avoid alcohol; concurrent use increases risk of CNS depression and respiratory arrest. No specific food interactions; maintain usual diet. Grapefruit juice may slightly increase fentanyl levels via CYP3A4 inhibition but clinical significance is minimal with transdermal route.
Fentanyl is excreted in breast milk. M/P ratio approximately 0.4. Breastfeeding is generally not recommended during Duragesic-75 use due to risk of infant sedation and respiratory depression. If used, monitor infant for unusual sleepiness, difficulty breathing, or poor feeding. Alternative analgesics are preferred.
Fentanyl is excreted in breast milk in low amounts (M/P ratio ~0.4-0.5). Single doses are unlikely to harm infant, but chronic use may cause sedation or respiratory depression in the neonate. Monitor for drowsiness, poor feeding. Benefit-risk assessment recommended.
No specific dose adjustments are established for Duragesic-75 in pregnancy. Fentanyl pharmacokinetics may be altered due to increased plasma volume, renal clearance, and hepatic metabolism; however, transdermal absorption may be inconsistent. Use lowest effective dose for shortest duration. Consider alternative opioids with more pregnancy data. Taper dose before delivery to reduce NAS risk.
Pregnancy may increase clearance of fentanyl due to expanded plasma volume and enhanced hepatic metabolism. Higher doses may be required for adequate analgesia, especially in the third trimester. Postpartum dose reduction may be needed. Individualize based on response and adverse effects.
Apply the patch to a flat, non-hairy area of the upper body or arm. Do not use on skin that is irritated, cut, or scarred.,Do not expose the patch to direct heat sources like heating pads, electric blankets, hot tubs, or sunbathing—this can cause a dangerous overdose.,Wash hands after handling the patch. Dispose of used patches by folding sticky sides together and flushing down toilet per FDA guidelines.,Remove the old patch and apply the new patch to a different skin site every 72 hours (3 days). Rotate sites to avoid skin irritation.,Do not cut, chew, or damage the patch—this can lead to rapid release of fentanyl and fatal overdose.,Store patches in a secure place away from children and pets. Accidental exposure can be fatal.,Common side effects include nausea, vomiting, constipation, dizziness, and drowsiness. Report severe drowsiness, confusion, difficulty breathing, or signs of an allergic reaction.,Avoid alcohol, other opioids, benzodiazepines, and sedatives as they increase risk of respiratory depression.,Do not stop using this medication suddenly; taper with prescriber to avoid withdrawal symptoms.,Seek emergency care for symptoms of overdose: slow or shallow breathing, extreme drowsiness, or unresponsiveness.
Apply patch to clean, dry, hairless skin on chest or back, avoiding scars, lesions, or irritated skin.,Do not cut, tear, or alter the patch in any way; this can cause rapid, fatal drug absorption.,Wash hands after applying or removing patch; avoid touching eyes or mucous membranes.,Keep away from children and pets; used patches should be folded, placed in original packaging, and disposed of per local drug take-back programs.,Avoid hot tubs, saunas, electric blankets, heating pads, or prolonged sun exposure while wearing patch; fever can increase absorption.,Do not drink alcohol while using fentanyl; it can cause severe drowsiness, respiratory depression, and death.,Common side effects include nausea, constipation, drowsiness, and dizziness. Contact healthcare provider if you experience confusion, slow or shallow breathing, or severe sedation.